SRPT Stock Analysis: Sarepta Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.203m USD | 12M Return: 14.9% | US8036071004 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 48.4M
Qual. Beats: 0
Rev. Trend: 85.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sarepta Therapeutics is a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company that develops RNA-targeted therapeutics, siRNA-based drugs, and gene therapies, with a focus on rare diseases. The company markets four approved treatments for Duchenne muscular dystrophy (DMD): EXONDYS 51, VYONDYS 53, and AMONDYS 45, which are exon-skipping therapies for patients with specific dystrophin gene mutations, and ELEVIDYS, an AAV-based gene therapy. Sarepta also has a clinical pipeline that includes SRP-9003 for LGMD2E, and two Phase 1/2a RNAi candidates, SRP-1001 and SRP-1003, targeting facioscapulohumeral muscular dystrophy and myotonic dystrophy, respectively. The company supports its development programs through a network of collaboration and license agreements with partners including Roche, Arrowhead Pharmaceuticals, Nationwide Childrens Hospital, Hansa Biopharma, and several academic institutions. Founded in 1980 and listed on NASDAQ under the ticker SRPT, Sarepta operates within the biotechnology subsector of healthcare, a segment where firms typically face long development timelines, significant regulatory risk, and dependence on a small number of approved products for revenue concentration.
- ELEVIDYS sales momentum and label expansion drive revenue
- Duchenne exon-skipping franchise faces competitive and pricing pressure
- FDA safety review on gene therapy clouds commercial outlook
| Net Income: -136.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 8.21 > 1.0 |
| NWC/Revenue: 87.16% < 20% (prev 70.00%; Δ 17.17% < -1%) |
| CFO/TA -0.03 > 3% & CFO -91.7m > Net Income -136.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.4m) vs 12m ago -1.12% < -2% |
| Gross Margin: 58.56% > 18% (prev 79.28%; Δ -20.73% > 0.5%) |
| Asset Turnover: 57.49% > 50% (prev 67.44%; Δ -9.95% > 0%) |
| Interest Coverage Ratio: -1.02 > 6 (EBIT TTM -59.3m / Interest Expense TTM 58.4m) |
| A: 0.54 (Total Current Assets 2.22b - Total Current Liabilities 502.9m) / Total Assets 3.19b |
| B: -1.43 (Retained Earnings -4.55b / Total Assets 3.19b) |
| C: -0.02 (EBIT TTM -59.3m / Avg Total Assets 3.43b) |
| D: 0.92 (Book Value of Equity 1.53b / Total Liabilities 1.66b) |
| Altman-Z'' = -0.26 = B |
| DSRI: 1.00 (Receivables 482.6m/609.6m, Revenue 1.97b/2.48b) |
| GMI: 1.35 (GM 79.28% / 58.56%) |
| AQI: 1.18 (AQ_t 0.16 / AQ_t-1 0.14) |
| SGI: 0.80 (Revenue 1.97b / 2.48b) |
| TATA: -0.01 (NI -136.7m - CFO -91.7m) / TA 3.19b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of August 31, 2026, the stock is trading at USD 20.86 with a total of 3,612,129 shares traded. Over the past week, the price has changed by +11.02%, over one month by +34.06%, over three months by +18.46% and over the past year by +14.87%.
Current recommended Stop Loss: 19.50 (which is 6.5% or 1.2 ATR below the current price).
Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.1 | 5.9% |
P/E Forward = 7.874
P/S = 1.116
P/B = 1.492
P/EG = 159.25
Revenue TTM = 1.97b USD
EBIT TTM = -59.3m USD
EBITDA TTM = -14.6m USD
Long Term Debt = 847.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last fiscal year)
Debt = 1.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 198.2m
Net Debt = 455.6m USD (calculated: Debt 1.24b - CCE 788.5m)
Enterprise Value = 2.66b USD (2.20b + Debt 1.24b - CCE 788.5m)
Interest Coverage Ratio = -1.02 (Ebit TTM -59.3m / Interest Expense TTM 58.4m)
EV/FCF = -20.23x (Enterprise Value 2.66b / FCF TTM -131.5m)
FCF Yield = -4.94% (FCF TTM -131.5m / Enterprise Value 2.66b)
FCF Margin = -6.66% (FCF TTM -131.5m / Revenue TTM 1.97b)
Net Margin = -6.93% (Net Income TTM -136.7m / Revenue TTM 1.97b)
Gross Margin = 58.56% ((Revenue TTM 1.97b - Cost of Revenue TTM 818.2m) / Revenue TTM)
Gross Margin QoQ = 62.77% (prev 83.67%)
Tobins Q-Ratio = 0.83 (Enterprise Value 2.66b / Total Assets 3.19b)
Interest Expense / Debt = 4.69% (Interest Expense 58.4m / Debt 1.24b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.8m (EBIT -59.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.42 (Total Current Assets 2.22b / Total Current Liabilities 502.9m)
Debt / Equity = 0.81 (Debt 1.24b / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -31.24 (negative EBITDA) (Net Debt 455.6m / EBITDA -14.6m)
Debt / FCF = -3.47 (negative FCF - burning cash) (Net Debt 455.6m / FCF TTM -131.5m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.98% (Net Income -136.7m / Total Assets 3.19b)
RoE = -9.96% (Net Income TTM -136.7m / Total Stockholder Equity 1.37b)
RoCE = -2.67% (EBIT -59.3m / Capital Employed (Equity 1.37b + L.T.Debt 847.6m))
RoIC = -1.80% (negative operating profit) (NOPAT -46.8m / Invested Capital 2.60b)
WACC = 7.57% (E(2.20b)/V(3.45b) * Re(9.75%) + D(1.24b)/V(3.45b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 56.65 | Cagr: 2.78%
[DCF] Fair Price = unknown (Cash Flow -131.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: 85.71 | Revenue CAGR: 29.28% | SUE: 0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.39 | Chg30d=-21.73% | Revisions=-50% | Analysts=10
EPS current Year (2026-12-31): EPS=4.39 | Chg30d=-8.76% | Revisions=-57% | GrowthEPS=+187.0% | GrowthRev=-16.4%
EPS next Year (2027-12-31): EPS=2.57 | Chg30d=-4.00% | Revisions=+0% | GrowthEPS=-41.4% | GrowthRev=-24.8%
[Analyst] Revisions Ratio: -50% (up=2, down=9)